148 related articles for article (PubMed ID: 18926149)
1. The economic returns of pediatric clinical trials of antihypertensive drugs.
Baker-Smith CM; Benjamin DK; Grabowski HG; Reid ED; Mangum B; Goldsmith JV; Murphy MD; Edwards R; Eisenstein EL; Sun J; Califf RM; Li JS
Am Heart J; 2008 Oct; 156(4):682-8. PubMed ID: 18926149
[TBL] [Abstract][Full Text] [Related]
2. Economic return of clinical trials performed under the pediatric exclusivity program.
Li JS; Eisenstein EL; Grabowski HG; Reid ED; Mangum B; Schulman KA; Goldsmith JV; Murphy MD; Califf RM; Benjamin DK
JAMA; 2007 Feb; 297(5):480-8. PubMed ID: 17284698
[TBL] [Abstract][Full Text] [Related]
3. Labeling Changes and Costs for Clinical Trials Performed Under the US Food and Drug Administration Pediatric Exclusivity Extension, 2007 to 2012.
Sinha MS; Najafzadeh M; Rajasingh EK; Love J; Kesselheim AS
JAMA Intern Med; 2018 Nov; 178(11):1458-1466. PubMed ID: 30264138
[TBL] [Abstract][Full Text] [Related]
4. Six-Month Market Exclusivity Extensions To Promote Research Offer Substantial Returns For Many Drug Makers.
Kesselheim AS; Rome BN; Sarpatwari A; Avorn J
Health Aff (Millwood); 2017 Feb; 36(2):362-370. PubMed ID: 28100464
[TBL] [Abstract][Full Text] [Related]
5. Impact of pediatric exclusivity on drug labeling and demonstrations of efficacy.
Wharton GT; Murphy MD; Avant D; Goldsmith JV; Chai G; Rodriguez WJ; Eisenstein EL
Pediatrics; 2014 Aug; 134(2):e512-8. PubMed ID: 25022732
[TBL] [Abstract][Full Text] [Related]
6. Peer-reviewed publication of clinical trials completed for pediatric exclusivity.
Benjamin DK; Smith PB; Murphy MD; Roberts R; Mathis L; Avant D; Califf RM; Li JS
JAMA; 2006 Sep; 296(10):1266-73. PubMed ID: 16968851
[TBL] [Abstract][Full Text] [Related]
7. Pediatric exclusivity: evolving legislation and novel complexities within pediatric therapeutic development.
Rivera DR; Hartzema AG
Ann Pharmacother; 2014 Mar; 48(3):369-79. PubMed ID: 24311725
[TBL] [Abstract][Full Text] [Related]
8. Estimated Costs of Pivotal Trials for Novel Therapeutic Agents Approved by the US Food and Drug Administration, 2015-2016.
Moore TJ; Zhang H; Anderson G; Alexander GC
JAMA Intern Med; 2018 Nov; 178(11):1451-1457. PubMed ID: 30264133
[TBL] [Abstract][Full Text] [Related]
9. Trials of antihypertensive therapies in children.
Wells TG
Blood Press Monit; 1999; 4(3-4):189-92. PubMed ID: 10490874
[TBL] [Abstract][Full Text] [Related]
10. Oral antihypertensive trial design and analysis under the pediatric exclusivity provision.
Pasquali SK; Sanders SP; Li JS
Am Heart J; 2002 Oct; 144(4):608-14. PubMed ID: 12360155
[TBL] [Abstract][Full Text] [Related]
11. [Pediatric drug development: ICH harmonized tripartite guideline E11 within the United States of America, the European Union, and Japan].
Pflieger M; Bertram D
Arch Pediatr; 2014 Oct; 21(10):1129-38. PubMed ID: 25175054
[TBL] [Abstract][Full Text] [Related]
12. Comparison of Sales Income and Research and Development Costs for FDA-Approved Cancer Drugs Sold by Originator Drug Companies.
Tay-Teo K; Ilbawi A; Hill SR
JAMA Netw Open; 2019 Jan; 2(1):e186875. PubMed ID: 30644967
[TBL] [Abstract][Full Text] [Related]
13. The Economic Contribution of Industry-Sponsored Pharmaceutical Clinical Trials.
Tran DT; Akpinar I; Fedorak R; Jonsson E; Mackey J; Richer L; Jacobs P
J Pharm Pharm Sci; 2017; 20(1):407-414. PubMed ID: 29197429
[TBL] [Abstract][Full Text] [Related]
14. Research and development costs for new drugs by therapeutic category. A study of the US pharmaceutical industry.
DiMasi JA; Hansen RW; Grabowski HG; Lasagna L
Pharmacoeconomics; 1995 Feb; 7(2):152-69. PubMed ID: 10155302
[TBL] [Abstract][Full Text] [Related]
15. Estimating the cost of new drug development: is it really 802 million dollars?
Adams CP; Brantner VV
Health Aff (Millwood); 2006; 25(2):420-8. PubMed ID: 16522582
[TBL] [Abstract][Full Text] [Related]
16. The economics of pediatric formulation development for off-patent drugs.
Milne CP; Bruss JB
Clin Ther; 2008 Nov; 30(11):2133-45. PubMed ID: 19108801
[TBL] [Abstract][Full Text] [Related]
17. Drug costs: research and development costs: the great illusion.
Prescrire Int; 2004 Feb; 13(69):32-6. PubMed ID: 15055226
[TBL] [Abstract][Full Text] [Related]
18. Research and Development Spending to Bring a Single Cancer Drug to Market and Revenues After Approval.
Prasad V; Mailankody S
JAMA Intern Med; 2017 Nov; 177(11):1569-1575. PubMed ID: 28892524
[TBL] [Abstract][Full Text] [Related]
19. [No bluff to be discovered in clinical trials].
Berglund T
Lakartidningen; 2009 Mar 25-31; 106(13):952-3. PubMed ID: 19441200
[No Abstract] [Full Text] [Related]
20. [ACCOMPLISH and the risks with company sponsored clinical trials].
Furberg C
Lakartidningen; 2009 Feb 11-17; 106(7):450. PubMed ID: 19350775
[No Abstract] [Full Text] [Related]
[Next] [New Search]